Drugs / LUBT010
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04690556 | Sep 2020 → May 2024 | wet macular degeneration | Lupin Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUBT010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04690556 ↗ |
| Known as | ranibizumab | “LUBT010 (proposed ranibizumab biosimilar) 0.5 mg via intravitreal injection once monthly” NCT04690556 ↗ |
| Route | Intravitreal | “via intravitreal injection” NCT04690556 ↗ |